国家医保局、卫健委：“真支持创新、支持真创新、支持差异化创新”

Group 1 - The core viewpoint of the news is the introduction of measures to support the high-quality development of innovative drugs in China, focusing on various aspects such as research and development, insurance coverage, clinical application, and payment capabilities [1][3]. - The measures include 16 specific actions aimed at providing comprehensive support for the entire chain of innovative drug development, from research to market access and payment [1]. - A new commercial health insurance innovative drug directory will be established, which will include drugs with high innovation, significant clinical value, and benefits for patients that exceed the basic medical insurance coverage [1][2]. Group 2 - The National Healthcare Security Administration (NHSA) will promote the development of innovative drugs in the global market by building platforms, expanding overseas markets, and providing price support [2]. - The measures aim to create a new landscape for innovative drug research and development that is guided by clinical value, encouraging investment and aligning with treatment needs [3]. - The establishment of a multi-channel payment system for innovative drugs will enhance accessibility and encourage reasonable use, addressing concerns related to the availability of innovative drugs [3].